Stockreport

Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease

Viridian Therapeutics, Inc.  (VRDN) 
PDF - PDUFA target action date of June 30, 2026 -- Priority Review designation is granted to applications for drugs that, if approved, would be a significant improvement in [Read more]